Anti-DLL4 (OMP-21M18, demcizumab)
OncoMed's lead anti-cancer stem cell therapeutic, OMP-21M18, is a monoclonal antibody optimized to block a key signaling pathway in cancer stem cells. Specifically, OMP-21M18 selectively targets Delta-like ligand 4 (DLL4), an activator of Notch signaling, which is a pathway known to be important in cancer stem cells and cancer.
Blocking DLL4 results in broad-spectrum anti-tumor activity via multiple mechanisms, including disrupting angiogenesis, inhibiting cancer stem cell growth and promoting cell differentiation. OMP-21M18 has demonstrated single-agent activity in a Phase 1 study in heavily-pretreated solid tumor patients, and is currently advancing in Phase Ib combination studies with standard chemotherapy in advanced non-small cell lung and pancreatic cancers.
OncoMed has a preclinical program that targets both DLL4 and VEGF.
OMP-59R5 is an antibody, screened against Notch2, that binds both the Notch2 and Notch3 receptors. OncoMed initiated single-agent Phase 1 clinical testing of OMP-59R5 in advanced solid tumor patients in 2011. In 2012, a Phase 1b/2 trial in pancreatic cancer was initiated.
OncoMed is currently advancing a third Notch pathway antibody candidate in Phase 1 clinical testing.
Anti-Fzd7 (vantictumab, OMP-18R5)
Vantictumab is OncoMed’s lead program in the Wnt pathway. Screened against the Frizzled 7 receptor, the antibody binds a conserved epitope on five of the Frizzled receptors. It has been shown in preclinical studies to induce tumor cell differentiation. Vantictumab entered Phase 1 clinical testing in 2011.
OncoMed is currently advancing a second Wnt pathway biologic in Phase 1 clinical trials.
Wnt 3rd Biologic
OncoMed is currently advancing a third Wnt pathway biologic in preclinical studies.
Wnt Small Molecules
OncoMed and Bayer HealthCare are jointly working to discover small molecules targeting the Wnt Pathway as part of the strategic collaboration announced in June 2010.
OncoMed has multiple new pathway discovery and preclinical efforts advancing in-house. These programs are emerging from the company’s focused efforts in cancer stem cell and cancer biology, expertise in mAb and protein therapeutics, and translational/predictive medicine. These efforts include programs in the RSPO-LGR pathway